Corteva (CTVA) is considering splitting up its seed and pesticide units, but BMO Capital is not convinced that a break-up would be value-enhancing, the analyst tells investors in a research note. The firm, which has an Outperform rating and $86 price target on the shares, says that sum-of-the-parts support for a break-up isn’t clear, and notes that the U.S. may not allow foreign companies to acquire domestic IP, and questions how the PFAS liability would split between CP and seeds standalones.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CTVA:
- Corteva’s Strong Market Position and Growth Potential Justify Buy Rating Despite Split Concerns
- Corteva’s Strategic Positioning and Financial Strength Drive Buy Rating
- Corteva mulls separation of seed, pesticide units, WSJ reports
- Corteva exploring breakup of company, WSJ reports
- Corteva jumps 3% to $75.09 after WSJ report of potential breakup